Focal therapy for prostate cancer – robotic HIFU is available in Singapore
What is prostate cancer?
Prostate cancer is the 3 rd most common cancer affecting men in Singapore. Majority of men with prostate cancer patients do not have urinary problems or pain. They are diagnosed due to abnormal blood test called prostate specific antigen (PSA) and subsequent prostate biopsy that shows cancer cells.
What is focal therapy of prostate cancer?
Focal therapy uses strong energy that concentrates to destroy their specific targets. One of the energy sources is high intensity focused ultrasound (HIFU), which has been tested and approved for accurate and effective treatment of localised prostate cancer.
During the HIFU procedure, there are no radiation, no cutting and no surgical scars.
Advantages of focal therapy for prostate cancer using HIFU Since focal therapy using HIFU only affects the selected areas of the prostate, there is less chance of urinary incontinence and less chance of damaging the nerves for penile erection.
What is Focal One?
Focal One device is the robotic HIFU machine that was approved by US Food and Drug Administration (FDA) in June 2018 and subsequently by Health Sciences Authority (HSA) in Singapore. It uses the latest technology for precise treatment of specific prostate tissues without damaging non-target areas. Focal One also has capabilities for MRI-ultrasound fusion image processing, precision targeting with robotic-assisted control, safety features to
prevent overheating of rectal wall, and ability to check for adequate treatment using ultrasound and contrast-enhanced microbubbles.
Who may be suitable for Focal Therapy?
Prostate cancer patients who may be suitable include:
Prostate cancer patients who may be suitable include:
- Newly diagnosed prostate cancer that is localised within the prostate gland
- Prostate cancer that recurred after previous radiotherapy
